Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Envafolimab + Regorafenib

Stage Phase 2

Sponsor Peking University

Class anti-PD-L1 (with regorafenib)

Target PD-L1 (TEC-0014)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06772233

A Phase II, Open-label, Multicenter, Randomized Controlled Clinical Trial Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment.

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT06772233

Registry NCT06772233

Phase Phase 2

Status Not yet recruiting

Enrollment 100

Start 2025-07-30

Primary completion 2027-07-30

Study completion 2028-07-30

Catalyst Primary completion. 07.30.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.